Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 339

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 339
---
,828 61,679,800 

(a) Excludes amortization of intangible assets.

See accompanying notes.

93

Supernus Pharmaceuticals, Inc.

Consolidated Statements of Comprehensive Earnings

(in thousands) Year Ended December 31, 202420232022Net earnings$73,865 $1,316 $60,711 Other comprehensive gain (loss)Unrealized gain (loss) on marketable securities, net of tax404 2,617 (4,749)Other comprehensive gain (loss)404 2,617 (4,749)Comprehensive earnings$74,269 $3,933 $55,962 

See accompanying notes.

94

Supernus Pharmaceuticals, Inc.

Consolidated Statements of Changes in Stockholders' Equity

(in thousands, except share data)Common StockAdditionalPaid-inCapitalAccumulatedOtherComprehensiveEarnings (Loss)RetainedEarningsTotalStockholders'Equity SharesAmountBalance, December 31, 202153,256,094 $53 $434,337 $1,539 $379,922 $815,851 Cumulative effect of adoption of ASU 2020-06— — (56,212)— 40,612 (15,600)Balance, January 1, 202253,256,094 53 378,125 1,539 420,534 800,251 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 17,568 — — 17,568 Issuance of common stock related to employee stock purchase plan and share-based awards997,702 1 12,422 — — 12,423 Net earnings— — — — 60,711 60,711 Unrealized loss on marketable securities, net of tax— — — (4,749)— (4,749)Balance, December 31, 202254,253,796 54 408,115 (3,210)481,245 886,204 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 26,759 — — 26,759 Issuance of common stock related to employee stock purchase plan and share-based awards469,560 1 4,619 — —